Bank S, Zimmerman H, Smolow C, Kranz V
Gut. 1985 Jun;26(6):603-6. doi: 10.1136/gut.26.6.603.
This study investigated whether ulcer prevention would be greater with the combined use of an acid-inhibiting agent, ranitidine, given together with a mucosal-protective agent, sucralphate. Duodenal ulcers were induced in rats with the secretagogues pentagastrin and bethanechol. Subtherapeutic doses of ranitidine (5 mg/kg/6 hours) and sucralphate (50 mg/6 hour) yielded an ulcer index of 4.0 and 4.1 respectively, not significantly different from the control (untreated) ulcer index of 4.3. Therapeutic doses of ranitidine (20 mg/kg) and sucralphate (200 mg/animal) gave an ulcer index of 0.4 and 0.5 respectively. Subtherapeutic doses of ranitidine and sucralphate given in combination yielded an ulcer index of 0.7. Thus, subtherapeutic doses of ranitidine and sucralphate given in combination had a synergistic effect equal to therapeutic doses of each of these drugs given alone. The therapeutic implications of combined acid inhibiting drugs with mucosal protective drugs is discussed.
本研究调查了将抑酸剂雷尼替丁与黏膜保护剂硫糖铝联合使用时,预防溃疡的效果是否会更好。用促分泌剂五肽胃泌素和氨甲酰甲胆碱在大鼠中诱发十二指肠溃疡。雷尼替丁的亚治疗剂量(5毫克/千克/6小时)和硫糖铝(50毫克/6小时)产生的溃疡指数分别为4.0和4.1,与对照(未治疗)溃疡指数4.3无显著差异。雷尼替丁的治疗剂量(20毫克/千克)和硫糖铝(200毫克/只动物)产生的溃疡指数分别为0.4和0.5。亚治疗剂量的雷尼替丁和硫糖铝联合使用产生的溃疡指数为0.7。因此,亚治疗剂量的雷尼替丁和硫糖铝联合使用具有与单独使用每种药物的治疗剂量相同的协同作用。文中讨论了联合使用抑酸药物和黏膜保护药物的治疗意义。